Location: Foreign Animal Disease Research
Project Number: 8064-32000-057-51-I
Project Type: Interagency Reimbursable Agreement
Start Date: Jun 12, 2013
End Date: Sep 30, 2017
This research project seeks to provide the necessary documentation of the duration of protective immunity against Foot-and-Mouth Disease Virus (FMDV) infection following vaccination with the newly licensed Ad5FMDV recombinant vaccine. Specific objectives include: 1. Obtain regulatory approval to use Ad5FMDV produced by GenVec/Merial at the University of Vermont (UVM). 2. Determine the duration of protective immunity using live virus challenge. 3. Determine the duration of protective immunity following a prime/boost vaccination protocol using live virus challenge. 4. Determine of correlates of protection against infection following Ad5FMDV vaccination.
1. Regulatory approval to use Ad5FMDV produced by GenVec/Merial at UVM. In order to initiate studies at Miller Farm on the UVM campus, approvals will be requested from; the Center for Veterinary Biologies, USDA, APHIS, the State of Vermont and UVM. Animal use approval will be prepared and submitted to the Institutional Animal Care and Use Committees at UVM and PIADC and the biosafety staff at UVM. Consultations will be done throughout the process with; the College of Agriculture and Life Sciences at UVM, state veterinarian of Vermont and the Vermont Dairyman’s Association. 2. Steers from the UVM herd will be typed for major histocompatibility complex (MHC) expression and vaccinated with Ad5FMDV intramuscularly, transdermally and subcutaneously in groups of 25 respectively. These cattle will be challenged at three month intervals, starting at month three at ARS, PIADC with virulent FMDV strain A24. The animals will then be assessed for protection. 3. Steers from the UVM herd will be typed for MHC expression and vaccinated with Ad5FMDV as detailed in objective 2. Following the primary vaccination 25 animals will receive a boost at 3,6,9 and 12 months. These cattle will be sent to ARS, PIADC for challenge with virulent FMDV strain A24. The animals will be assessed for protection. 4. Using the UVM cattle which are genetically defined for the immune response genes of MHC, we can identify antigen specific cells that mediate both anti-viral cellular responses of both B and T lymphocytes. An analysis will be conducted on adaptive immune response generated by the cattle in the above studies. Specific areas of study will the analysis of B cell response in peripheral blood and application of MHC class II tetramer technology for analysis of CD4 helper T cells.